EX-99.1
Published on April 15, 2021
2020 | Exhibit 99.1
Key 2020 Financial Highlights and Accomplishments OUR COMMON PURPOSE We save lives by improving patient care. OUR VISION By providing uncompromising quality, exceptional service and innovative solutions, we are becoming the world’s leading cancer testing and information company. OUR VALUES Quality, Integrity, Accountability, Teamwork, and Innovation Becoming the World’s Leading Cancer Testing and Information Company
Clinical Tests Performed(3) (in thousands) Pharma Revenue and Backlog (in millions) $ in Thousands 2018 2019 2020 Revenue $276,741 $408,830 $444,448 % Growth 15.2% 47.7% 8.7% Adjusted EBITDA (Non-GAAP)(1) $43,552 $57,217 $34,842 % Growth (Decline) 29.6% 31.4% (39.1%) Net Income $2,640 $8,006 $4,172 Clinical Testing Volume(2) 749,902 987,539 976,069 % Growth (Decline) 14.1% 31.7% (1.2%) Revenue, Adjusted EBITDA, Net Income and Clinical Testing Volume
Dear Fellow Shareholders:
Dear Fellow Shareholders (cont.)
Douglas M. VanOort Chairman of the Board of Directors and Chief Executive Officer
Critical Success Factors and Actions 2021 Focus: Sustainable Growth Contribute and Connect Empower Employees and Provide Meaningful Work Experiences Improve Quality, Efficiency and Productivity Build New Products and Capabilities Consistently Achieve TAT Goals Build Sustainable Organization Transform IT Make Informatics Enterprise-wide Be a Market Leader in NGS World-Class Culture Uncompromising Quality and Exceptional Service Innovation and Growth Employee Engagement Employee Retention >88% Customer Satisfaction Client Retention >95% Shareholder Satisfaction Achieve Results >Plan Satisfaction Model COMMON PURPOSE We save lives by improving patient care. VISION By providing uncompromising quality, exceptional service and innovative solutions, we are becoming the world’s leading cancer testing and information company. VALUES Quality, Integrity, Accountability, Teamwork, Innovation.
Board of Directors Douglas M. VanOort Chairman and CEO Lynn A. Tetrault Lead Director Bruce K. Crowther Director Alison L. Hannah, M.D. Director Raymond R. Hipp Director Kevin C. Johnson Director Steven C. Jones Director Stephen M. Kanovsky Director Michael A. Kelly Director Rachel A. Stahler Director Corporate Offices Transfer Agent Independent Registered Public Accounting Firm Annual Meeting Stock Listing and Information Forward Looking Statements Corporate Information Corporate Officers Kathryn B. McKenzie Chief Financial Officer Denise E. Pedulla General Counsel and Corporate Secretary Robert J. Shovlin President, Clinical Services George A. Cardoza President, Pharma Services William B. Bonello President, Informatics Douglas M. Brown Chief Strategy and Corporate Development Officer Cynthia J. Dieter Chief Accounting Officer and Controller Jennifer M. Balliet Chief Culture Officer Stephanie K. Bywater Chief Compliance Officer Marcus B. Silva Chief Marketing Officer Medical Leadership Lawrence M. Weiss, M.D. Chief Medical Officer Sally S. Agersborg, M.D., Ph.D. Medical Director, Aliso Viejo, California Derek Lyle, M.D. Medical Director, Carlsbad, California and Fort Myers, Florida J. Christopher Mixon, M.D. Laboratory Director, Nashville, Tennessee David L. Morgan, M.D. Laboratory Director, Houston, Texas Yin Xu, M.D., Ph.D. Medical Director, Atlanta, Georgia Josette William Ragheb, M.D., Ph.D. Global Medical Director, Pharma Services
NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing, partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, immunohistochemistry, and morphologic analysis through our nation-wide network of CAP-accredited, CLIA-certified laboratories. Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.